X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to expand Confo’s ongoing R&D efforts in the discovery of next-generation medicines targeting Class B GPCRs using its patent-protected technology platform.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding March 28, 2024
Details:
The collaboration aims for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, leveraging confo's proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations.
Lead Product(s): GPCR Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2023
Details:
Under the terms of the agreement, Confo will lead the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2023
Details:
Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1 of CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) for the treatment of neuropathic pain.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $630.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement March 02, 2023
Details:
CFTX-1554 is a novel inhibitor of AT2R, a clinically precedented target for the treatment of neuropathic pain. CFTX-1554 interacts more efficiently with the AT2R binding site, resulting in improved properties.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
The grant will enable to further extend its current universal ConfoBody®, Cb35, toward other G proteins. The funds will also be used to identify additional universal ConfoBodies® for use in ConfoSensor® screening technology and lead neuropathic pain program, CFTX-1554.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Financing June 28, 2022
Details:
CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R), is being developed as a non-opioid approach to the treatment of neuropathic pain, while avoiding centrally mediated side effects, such as addiction and sedation.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The newly added patent cover Confo’s well-established small molecule screening capabilities, which led to the discovery of CFTX-1554 designed to address peripheral neuropathic pain while avoiding centrally mediated side effects, such as addiction and sedation.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
The agreement will leverage Confo’s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo’s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs.
Lead Product(s): Antibody Medicines
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2021
Details:
The grant covers clinical trial application-enabling studies to further characterize the pharmacology and safety of CFTX-1554 and the development of appropriate manufacturing protocols and translational biomarker studies to examine the mechanism of action of AT2R modulation.
Lead Product(s): CFTX-1554
Therapeutic Area: Neurology Product Name: CFTX-1554
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Funding March 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
